elranatamab + daratumumab + lenalidomide

**elranatamab + daratumumab + lenalidomide** is an investigational drug regimen combining three agents for the treatment of newly diagnosed, transplant-ineligible multiple myeloma. - **Elranatamab** is a humanized bispecific monoclonal antibody targeting both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T-cells, activating T-cells to induce targeted cytotoxicity of myeloma cells. - **Daratumumab** is a monoclonal antibody directed at CD38, a surface protein highly expressed on myeloma cells, leading to cell death by multiple immune-mediated mechanisms. - **Lenalidomide** is an immunomodulatory drug that enhances T-cell and natural killer cell function and inhibits cytokine release, with direct and indirect anti-tumor activity. This triple combination is being evaluated for efficacy (response rates, progression-free survival), safety, and minimal residual disease negativity in clinical trials, primarily for patients with multiple myeloma who are not candidates for stem cell transplant[1][2][3][5].

Brand names

Elrexfio (elranatamab)Darzalex (daratumumab)Revlimid (lenalidomide)

Other names

EDR (clinical shorthand for elranatamab + daratumumab + lenalidomide, in trials)elranatamab-bcmm (sometimes used for elranatamab)